Bifosfonates to Osteogenesis imperfect
Abstract
Background: Osteogenesis imperfect is a disease of genetic origin, which causes a defect in the formation of collagen type I, with the common feature of presenting congenital bone fragility and heterogeneous clinical manifestations that can range from a small number of fractures or osteopenia, to severe skeletal deformities with fatal results. It’s incidence is variable and there is no clear data in Colombia, equally affects all ethnicities and genders, with primary commitment to the long bones of the limbs, and sequels such as deformities, bone pain and functional limitation unwieldy for everyday activities, the personal and social development. It is classified into nine major subtypes according to the genetic, radiological and clinical characteristics, the last ones being the most important to discriminate between mild, moderate or severe and lethal disease, and determining prognosis and therapeutic interventions. Objective: Describe the current concepts of etiology, pathophysiology, emphasizing on therapeutic measures. Conclusions: It needs an interdisciplinary approach, which has been limited to conservative and surgical correction of deformities, without touching the intrinsic fragility of the disease. Bisphosphonates are effectives. It improves the quality of life and chances of surgical correction. Zoledronic acid is the most effective.Downloads
References
Montoya ÁC. Osteogenésis Imperfecta. Revista médica de Costa Rica y Centroamerica. 2007;64(580):161-5.
Shapiro JR. Osteogenesis imperfecta: questions and answers. Current Opinion in Pediatrics. 2009;21:709-16.
Tau C. Tratamiento de osteogénesis imperfecta con bifosfonatos. Medicina (Buenos Aires). 2007;67(4): 389-95.
Stephanie R. Starr TTR, Philip R. Fischer. Osteogenesis Imperfecta: Primary Care. Pediatrics in Review. 2010; 31(8): 54-64
Osteogenesis imperfecta: Clinical features and diagnosis. http://www.uptodate.com/osteogenesisimperfecta:clinicalfeaturesanddiagnosis (Consultado el 15 de Mayo de 2013)
Acosta MA. Osteogénesis imperfecta tipo III, reporte de un caso y revisión de la literatura. Revista de la Facultad Ciencias de la Salud. 2008; 10(4): 65-8
Oswaldo Lazala HS. Terapia con bifosfonatos en osteogénesis imperfecta. Revista Colombiana de Ortopedia y Traumatología. 2009; 23(3): 109-15.
Rodríguez G. Neonatal Presentation of Osteogenesis Imperfecta. Acta médica costarricense. 2009; 51(2): 114-8
Glorieux FH. Treatment of Osteogenesis Imperfecta: Who, Why, What? Hormone Research 2007; 68(5): 8–11.
Barnuevo G. Administración o no de bifosfonatos en pacientes con osteogenesis imperfecta inmediatamente postosteotomía. Quito, Ecuador: Universidad San Francisco de quito; 2008.
Fernández MC. Revisión bibliográfica sobre la Osteogénesis Imperfecta de las publicaciones más relevantes aparecidas los últimos 12 meses. Revista Universidad Rey Juan Carlos. 2008; 28: 1-8
Rauch F GF. Osteogenesis imperfecta. Lancet. 2004;363:1377-85
Glorieux FH. Osteogenesis imperfecta. Best Practice & Research Clinical Rheumatology. 2008; 22(1): 85-100.
Byers PH PS. Recessively inherited forms of osteogenesis imperfecta. . Annual review of Genetics. 2012: 475-97.
Marini JC, Blissett AR. New genes in bone development: What´s new in osteogenesis imperfecta. The journal of clinical endocrinology and metabolism. 2013; 14: 3095-3103.
Marini JC, Cabral WA, Barnes AM. Null mutations in LEPRE1 and CRTAP cause severe recessive osteogenesis imperfecta. Cell tissue research. 2010; 339(1): 59-70.
Semler O CM, Glorieux FH. Wormian bones in osteogenesis imperfecta: Correlation to clinical findings and genotype. American Journal of Genetics. 2010;152(7):1681-87.
Madu AE OJ. Pregnancy complicated by a severe form of foetal osteogenesis imperfecta in a 17-year-old primigravida: case report and overview of literature. The journal of maternal-fetal & neonatal medicine 2013; 26(7): 703-5.
Plotkin H. Syndromes with congenital brittle bones. BMC Pediatrics. 2004; 4(16)
Ben Amor M, Rauch F, MOnti E, Antoniazzi F. Osteogenesis imperfecta. Pediatric endocrinology reviews. 2013; 10(2): 397-405
Renaud A, Aucourt J, Weill J, Bigot J, Dieux A, Devisme L, et all. Radiographic features of osteogenesis imperfecta. Insights imaging. 2013; 4(4): 417-29.
Kuurila K KI, Johansson R, Grénman R. . Hearing loss in Finnish adults with osteogenesis imperfecta: a nationwide survey. Annals of Otology, Rhinology, and Laryngology. 2002; 111: 939-46.
Zeitlin L FF, Glorieux FH. . Modern approach to children with osteogenesis imperfecta. Journal Pediatrics Orthopedics. 2003; 12:77-87.
Wenstrup RJ WM, Starman BJ, Byers PH. Distinct biochemical phenotypes predict clinical severity in nonlethal variants of osteogenesis imperfecta. American Journal of Human Genetics. 1990; 46: 975-82.
Körkkö J A-KL, De Paepe A. . Analysis of the COL1A1 and COL1A2 genes by PCR amplification and scanning by conformation-sensitive gel electrophoresis identifies only COL1A1 mutations in 15 patients with osteogenesis imperfecta type I: identification of common sequences of null-allele mutations. American Journal of Human Genetics. 1998; 62(1): 98-110.
MP. W. Hypophosphatasia and the role of alkaline phosphatase in skeletal mineralization. Endocrine Reviews. 1994; 15(4): 439-61.
Chines A BA, McAlister W, Whyte M. Hypercalciuria in osteogenesis imperfecta: a follow-up study to assess renal effects. Bone. 1995;16: 333-9.
Edouard T, Glorieux FH, Rauch F. Predictors and correlates of vitamin D status in children and adolescents with osteogenesis imperfecta. The journal of clinical endocrinology and metabolism. 2011; 96(10): 3193-8
Edouard T, Husseini A, Glorieux FH, Rauch F. Serum 24,25-dihydroxyvitamin D concentrations in osteogenesis imperfecta: relationship to bone parameters. The journal of clinical endocrinology and metabolism. 2012; 97(4): 1243-9
Rauch F TR, Parfitt AM, Glorieux FH. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone. 2000; 26: 581-9.
McPherson E CM. Bruck syndrome (osteogenesis imperfecta with congenital joint contractures): review and report on the first North American case. American Journal of Genetics. 1997; 70: 28-31.
Capoen J DPA, Lauwers H. The osteoporosis pseudoglioma syndrome. Journal Belge de Radiologie. 1993;76: 224-5.
Whyte MP OS. Osteoprotegerin deficiency and juvenile Paget's disease. New England Journal of Medicine. 2002;347:175-84.
Smith R. Idiopathic juvenile osteoporosis: experience of twenty-one patients. . British Journal of Rheumatology. 1995; 34: 68-77.
Nieves M. Maltrato infantil: una dolorosa realidad puertas adentro. Desafíos. 2009; 23: 1-12.
Monti E MM, Fraschini P. Current and emerging treatments for the management of osteogenesis imperfecta. Journal of Therapeutics and Clinical Risk Management. 2010; 2010(6): 367-81.
Wilsford LD, Sullivan E, Mazur LJ. Risk factors for vitamin D deficiency in children with osteogenesis imperfecta. Journal of pediatric orthopedics. 2013: 33(5): 575-9
Rauch F GF. Bisphosphonate treatment in osteogenesis imperfecta: which drug, for whom, for how long?. Annals of Medicine. 2005; 37: 295-302.
Nicolaou N, Agrawal Y, Padman M, Fernandes JA, Bell MJ. Changing pattern of femoral fractures in osteogenesis imperfecta with prolonged use of bisphosphonates. 2012; 6(1): 21-7
Glorieux FH BN, Plotkin H. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. New England Journal of Medicine. 1998; 339: 947-52.
Sousa T, Bompadre V, White KK. Musculoskeletal functional outcomes in children with osteogenesis imperfecta: associations with disease severity and pamidronate therapy. Orthopaedic research report. 2013; 70-3
DiMeglio LA FL, McClintock C, Peacock M. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone. 2004; 35(5):1038-45.
Rauch F PH, Travers R. . Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. The Journal of Clinical Endocrinology and Metabolism 2003; 88: 986-92.
Alcausin MB, Briody J, Pacey V, Ault J, McQuade M, Bridge C, et al. Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age. Hormone research in paediatrics. 2013; 79(6): 333-40
Chilbule SK, Madhuri V. Complications of pamidronate therapy in paediatric osteoporosis. Journal of children orthopaedics. 2012; 6(1): 37-43.
Barros ER. Safety and effi cacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. Journal of pediatric endocrinology and metabolism. 2012; 25(5): 485-91.
Vuorimies I. Zoledronic Acid Treatment in Children with Osteogenesis Imperfecta. Hormone Research in Paedriatics. 2011; 75(5): 346-53.
Christou J, Johnson AR, Hodgson TA. Bisphosphonate - related osteonecrosis of the jaws and its relevance to children - A review. International journal of paediatric dentistry. 2013; 23(5): 330-37
Milano M, Wright T, Loechner KJ. Dental implications of osteogenesis imperfecta: treatment with IV bisphosphonate: Report of a case. Pediatric dentistry. 2011; 33(4): 349-52
Antoniazzi F MM, Fraschini P. Osteogenesis imperfecta: practical treatment guidelines. Paediatric Drugs. 2000; 2: 465-88.
Horwitz EM PD, Gordon PL. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood. 2001; 97: 1227-31.
Osteogenesis imperfecta: Management and prognosis. http://www.uptodate.com/osteogenesisimperfecta: Management and prognosis (Consultado el 15 de Mayo de 2011).
Niyibizi c, Wang S, Robbins PD. Gene therapy approaches for osteogenesis imperfecta. Gene Therapy. 2004; 11(04): 408-16.
.png)
